Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Oncogene Retrieve available abstracts of 109 articles: HTML format

Single Articles

April 2024
1. WANG X, Li X, Niu L, Lv F, et al
   FAK-LINC01089 negative regulatory loop controls chemoresistance and progression of small cell lung cancer.
   Oncogene. 2024 Apr 9. doi: 10.1038/s41388-024-03027.
   PubMed     Abstract available
   
   
   
2. ZHANG T, Su F, Wang B, Liu L, et al
   Ubiquitin specific peptidase 38 epigenetically regulates KLF transcription factor 5 to augment malignant progression of lung adenocarcinoma.
   Oncogene. 2024;43:1190-1202.
   PubMed     Abstract available
   
   
   March 2024
3. GUO J, Kim D, Gao J, Kurtyka C, et al
   Retraction Note: IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer.
   Oncogene. 2024 Mar 5. doi: 10.1038/s41388-024-02993.
   PubMed    
   
   
   
4. XU X, Qiu S, Zeng B, Huang Y, et al
   N(6)-methyladenosine demethyltransferase FTO mediated m(6)A modification of estrogen receptor alpha in non-small cell lung cancer tumorigenesis.
   Oncogene. 2024 Mar 5. doi: 10.1038/s41388-024-02992.
   PubMed     Abstract available
   
   
   
5. KUMAR V, Yochum ZA, Devadassan P, Huang EH, et al
   TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer.
   Oncogene. 2024 Mar 1. doi: 10.1038/s41388-024-02987.
   PubMed     Abstract available
   
   
   
6. MCCLELLAN B, Wilson CN, Brenner AJ, Jolly CA, et al
   Flotillin-1 palmitoylation is essential for its stability and subsequent tumor promoting capabilities.
   Oncogene. 2024;43:1063-1074.
   PubMed     Abstract available
   
   
   
7. HEIM TE, Hankins ML, Belayneh R, Douglas N, et al
   RNA-sequencing predicts a role of androgen receptor and aldehyde dehydrogenase 1A1 in osteosarcoma lung metastases.
   Oncogene. 2024;43:1007-1018.
   PubMed     Abstract available
   
   
   February 2024
8. GAROFALO M, Quintavalle C, Di Leva G, Zanca C, et al
   Editorial Expression of Concern: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.
   Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02989.
   PubMed    
   
   
   
9. TURKOWSKI K, Herzberg F, Gunther S, Weigert A, et al
   miR-147b mediated suppression of DUSP8 promotes lung cancer progression.
   Oncogene. 2024 Feb 23. doi: 10.1038/s41388-024-02969.
   PubMed     Abstract available
   
   
   January 2024
10. ZHANG Y, Liu L, Pei J, Ren Z, et al
    Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer.
    Oncogene. 2024 Jan 8. doi: 10.1038/s41388-023-02924.
    PubMed     Abstract available
    
    
    
11. OSER MG, MacPherson D, Oliver TG, Sage J, et al
    Genetically-engineered mouse models of small cell lung cancer: the next generation.
    Oncogene. 2024 Jan 8. doi: 10.1038/s41388-023-02929.
    PubMed     Abstract available
    
    
    
12. MA M, Zhuang J, Li H, Mi R, et al
    Low expression of ZFP36L1 in osteosarcoma promotes lung metastasis by inhibiting the SDC4-TGF-beta signaling feedback loop.
    Oncogene. 2024;43:47-60.
    PubMed     Abstract available
    
    
    December 2023
13. WANG L, Li H, Huang A, Zhao Y, et al
    Mutual regulation between TRIM21 and TRIM8 via K48-linked ubiquitination.
    Oncogene. 2023;42:3708-3718.
    PubMed     Abstract available
    
    
    November 2023
14. CHEN W, Wang F, Yu X, Qi J, et al
    LncRNA MIR31HG fosters stemness malignant features of non-small cell lung cancer via H3K4me1- and H3K27Ace-mediated GLI2 expression.
    Oncogene. 2023 Nov 10. doi: 10.1038/s41388-023-02883.
    PubMed     Abstract available
    
    
    
15. KOU F, Wu L, Zheng Y, Yi Y, et al
    HMGB1/SET/HAT1 complex-mediated SASH1 repression drives glycolysis and metastasis in lung adenocarcinoma.
    Oncogene. 2023;42:3407-3421.
    PubMed     Abstract available
    
    
    
16. SUN X, Dai Y, He J, Li H, et al
    D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC.
    Oncogene. 2023;42:3503-3513.
    PubMed     Abstract available
    
    
    October 2023
17. BAI Y, Zhou L, Zhang C, Guo M, et al
    Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer.
    Oncogene. 2023 Oct 20. doi: 10.1038/s41388-023-02866.
    PubMed     Abstract available
    
    
    
18. LIU Y, Zhang T, Deng J, Huang Q, et al
    The cytotoxicity of (gammadelta)T cells in non-small cell lung cancer mediated via coordination of the BCL-2 and AKT pathways.
    Oncogene. 2023 Oct 7. doi: 10.1038/s41388-023-02852.
    PubMed     Abstract available
    
    
    
19. WANG Y, Liu X, Wang M, Wang Y, et al
    UBE3B promotes breast cancer progression by antagonizing HIF-2alpha degradation.
    Oncogene. 2023 Oct 2. doi: 10.1038/s41388-023-02842.
    PubMed     Abstract available
    
    
    
20. CUI P, Li J, Tao H, Li X, et al
    Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis.
    Oncogene. 2023;42:3098-3112.
    PubMed     Abstract available
    
    
    August 2023
21. CUI Q, Wang W, Namani A, Wang H, et al
    NRF2 has a splicing regulatory function involving the survival of motor neuron (SMN) in non-small cell lung cancer.
    Oncogene. 2023 Aug 12. doi: 10.1038/s41388-023-02799.
    PubMed     Abstract available
    
    
    June 2023
22. LUO R, Chyr J, Wen J, Wang Y, et al
    A novel integrated approach to predicting cancer immunotherapy efficacy.
    Oncogene. 2023;42:1913-1925.
    PubMed     Abstract available
    
    
    
23. ZHAO S, Li J, Xia Q, Liu K, et al
    New perspectives for targeting therapy in ALK-positive human cancers.
    Oncogene. 2023;42:1959-1969.
    PubMed     Abstract available
    
    
    
24. ZHONG H, Lu W, Tang Y, Wiel C, et al
    SOX9 drives KRAS-induced lung adenocarcinoma progression and suppresses anti-tumor immunity.
    Oncogene. 2023;42:2183-2194.
    PubMed     Abstract available
    
    
    May 2023
25. BERR AL, Wiese K, Dos Santos G, Koch CM, et al
    Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer.
    Oncogene. 2023 May 9. doi: 10.1038/s41388-023-02703.
    PubMed     Abstract available
    
    
    
26. ROMANO G, Le P, Nigita G, Saviana M, et al
    A-to-I edited miR-411-5p targets MET and promotes TKI response in NSCLC-resistant cells.
    Oncogene. 2023;42:1597-1606.
    PubMed     Abstract available
    
    
    March 2023
27. HUANG JQ, Duan LX, Liu QY, Li HF, et al
    Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3beta Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer.
    Oncogene. 2023 Mar 3. doi: 10.1038/s41388-023-02645.
    PubMed     Abstract available
    
    
    February 2023
28. LIU B, Zhang J, Meng X, Xie SM, et al
    HDAC6-G3BP2 promotes lysosomal-TSC2 and suppresses mTORC1 under ETV4 targeting-induced low-lactate stress in non-small cell lung cancer.
    Oncogene. 2023 Feb 23. doi: 10.1038/s41388-023-02641.
    PubMed     Abstract available
    
    
    
29. SINGH A, Busacca S, Gaba A, Sheaff M, et al
    BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms.
    Oncogene. 2023;42:572-585.
    PubMed     Abstract available
    
    
    January 2023
30. WANG L, Li D, Su X, Zhao Y, et al
    AGO4 suppresses tumor growth by modulating autophagy and apoptosis via enhancing TRIM21-mediated ubiquitination of GRP78 in a p53-independent manner.
    Oncogene. 2023;42:62-77.
    PubMed     Abstract available
    
    
    December 2022
31. IWAI M, Kajino T, Nakatochi M, Yanagisawa K, et al
    Long non-coding RNA TILR constitutively represses TP53 and apoptosis in lung cancer.
    Oncogene. 2022 Dec 15. doi: 10.1038/s41388-022-02546.
    PubMed     Abstract available
    
    
    
32. SHIA DW, Choi W, Vijayaraj P, Vuong V, et al
    Targeting PEA3 transcription factors to mitigate small cell lung cancer progression.
    Oncogene. 2022 Dec 13. doi: 10.1038/s41388-022-02558.
    PubMed     Abstract available
    
    
    
33. GIANNI M, Terao M, Kurosaki M, Paroni G, et al
    Correction: S100A3 a partner protein regulating the stability/activity of RARalpha and PML-RARalpha in cellular models of breast/lung cancer and acute myeloid leukemia.
    Oncogene. 2022 Dec 7. doi: 10.1038/s41388-022-02564.
    PubMed    
    
    
    
34. AN J, Nagaki Y, Motoyama S, Kuze Y, et al
    Identification of Galectin-7 as a crucial metastatic enhancer of squamous cell carcinoma associated with immunosuppression.
    Oncogene. 2022;41:5319-5330.
    PubMed     Abstract available
    
    
    November 2022
35. THIRUSANGU P, Ray U, Sarkar Bhattacharya S, Oien DB, et al
    Correction to: PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma.
    Oncogene. 2022 Nov 28. doi: 10.1038/s41388-022-02470.
    PubMed    
    
    
    October 2022
36. SEMBA S, Trapasso F, Fabbri M, McCorkell KA, et al
    Correction to: Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential.
    Oncogene. 2022 Oct 20. pii: 10.1038/s41388-022-02472.
    PubMed    
    
    
    September 2022
37. ZHENG QW, Ni QZ, Zhu B, Liang X, et al
    PPDPF promotes lung adenocarcinoma progression via inhibiting apoptosis and NK cell-mediated cytotoxicity through STAT3.
    Oncogene. 2022;41:4244-4256.
    PubMed     Abstract available
    
    
    
38. HU M, Bao R, Lin M, Han XR, et al
    ALK fusion promotes metabolic reprogramming of cancer cells by transcriptionally upregulating PFKFB3.
    Oncogene. 2022;41:4547-4559.
    PubMed     Abstract available
    
    
    August 2022
39. HAMAD SH, Montgomery SA, Simon JM, Bowman BM, et al
    Correction: TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice.
    Oncogene. 2022 Aug 25. pii: 10.1038/s41388-022-02442.
    PubMed    
    
    
    
40. YI Y, Li P, Huang Y, Chen D, et al
    P21-activated kinase 2-mediated beta-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
    Oncogene. 2022 Aug 19. pii: 10.1038/s41388-022-02438.
    PubMed     Abstract available
    
    
    July 2022
41. BIAN T, Wang Y, Botello JF, Hu Q, et al
    LKB1 phosphorylation and deactivation in lung cancer by NNAL, a metabolite of tobacco-specific carcinogen, in an isomer-dependent manner.
    Oncogene. 2022 Jul 14. pii: 10.1038/s41388-022-02410.
    PubMed     Abstract available
    
    
    
42. THIRUSANGU P, Ray U, Sarkar Bhattacharya S, Oien DB, et al
    PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma.
    Oncogene. 2022 Jul 8. pii: 10.1038/s41388-022-02391.
    PubMed     Abstract available
    
    
    
43. YOU A, Tian W, Yuan H, Gu L, et al
    TTC22 promotes m6A-mediated WTAP expression and colon cancer metastasis in an RPL4 binding-dependent pattern.
    Oncogene. 2022 Jul 7. pii: 10.1038/s41388-022-02402.
    PubMed     Abstract available
    
    
    
44. ALFARO-ARNEDO E, Lopez IP, Pineiro-Hermida S, Canalejo M, et al
    IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression.
    Oncogene. 2022;41:3625-3639.
    PubMed     Abstract available
    
    
    
45. ZENG Z, Xu S, Wang F, Peng X, et al
    HAO1-mediated oxalate metabolism promotes lung pre-metastatic niche formation by inducing neutrophil extracellular traps.
    Oncogene. 2022;41:3719-3731.
    PubMed     Abstract available
    
    
    June 2022
46. GALLARDO A, Molina A, Asenjo HG, Lopez-Onieva L, et al
    EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization.
    Oncogene. 2022 Jun 9. pii: 10.1038/s41388-022-02375.
    PubMed     Abstract available
    
    
    
47. UESHIMA S, Fang J
    Histone H3K9 methyltransferase SETDB1 augments invadopodia formation to promote tumor metastasis.
    Oncogene. 2022;41:3370-3380.
    PubMed     Abstract available
    
    
    May 2022
48. HAMAD SH, Montgomery SA, Simon JM, Bowman BM, et al
    TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice.
    Oncogene. 2022 May 16. pii: 10.1038/s41388-022-02348.
    PubMed     Abstract available
    
    
    
49. LU X, Wang J, Wang W, Lu C, et al
    Copy number amplification and SP1-activated lncRNA MELTF-AS1 regulates tumorigenesis by driving phase separation of YBX1 to activate ANXA8 in non-small cell lung cancer.
    Oncogene. 2022 May 4. pii: 10.1038/s41388-022-02292.
    PubMed     Abstract available
    
    
    
50. LI X, Chen H, Zhang L, Chen L, et al
    27-hydroxycholesterol linked high cholesterol diet to lung adenocarcinoma metastasis.
    Oncogene. 2022;41:2685-2695.
    PubMed     Abstract available
    
    
    April 2022
51. LIU Y, Luo Y, Yan S, Lian YF, et al
    CRL2(KLHDC3) mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression.
    Oncogene. 2022 Apr 25. pii: 10.1038/s41388-022-02318.
    PubMed     Abstract available
    
    
    
52. TYAGI A, Wu SY, Sharma S, Wu K, et al
    Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasis.
    Oncogene. 2022 Apr 23. pii: 10.1038/s41388-022-02322.
    PubMed     Abstract available
    
    
    
53. BAUMER N, Tiemann J, Scheller A, Meyer T, et al
    Targeted siRNA nanocarrier: a platform technology for cancer treatment.
    Oncogene. 2022;41:2210-2224.
    PubMed     Abstract available
    
    
    
54. IKEUCHI H, Hirose T, Ikegami M, Takamochi K, et al
    Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
    Oncogene. 2022;41:2470-2479.
    PubMed     Abstract available
    
    
    March 2022
55. WANG C, Zhang S, Ma B, Fu Y, et al
    TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression.
    Oncogene. 2022 Mar 7. pii: 10.1038/s41388-022-02260.
    PubMed     Abstract available
    
    
    
56. WU WR, Shi XD, Zhang FP, Zhu K, et al
    Activation of the Notch1-c-myc-VCAM1 signalling axis initiates liver progenitor cell-driven hepatocarcinogenesis and pulmonary metastasis.
    Oncogene. 2022 Mar 7. pii: 10.1038/s41388-022-02246.
    PubMed     Abstract available
    
    
    
57. MA G, Deng Y, Qian L, Vallega KA, et al
    Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both.
    Oncogene. 2022;41:1691-1700.
    PubMed     Abstract available
    
    
    
58. JEONG HS, Lee DH, Kim SH, Lee CH, et al
    Hyperglycemia-induced oxidative stress promotes tumor metastasis by upregulating vWF expression in endothelial cells through the transcription factor GATA1.
    Oncogene. 2022;41:1634-1646.
    PubMed     Abstract available
    
    
    
59. HONG SY, Lu YC, Hsiao SH, Kao YR, et al
    Stabilization of AURKA by the E3 ubiquitin ligase CBLC in lung adenocarcinoma.
    Oncogene. 2022;41:1907-1917.
    PubMed     Abstract available
    
    
    February 2022
60. TSUBOYAMA N, Wang R, Szczepanski AP, Chen H, et al
    Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.
    Oncogene. 2022 Feb 22. pii: 10.1038/s41388-022-02240.
    PubMed     Abstract available
    
    
    
61. LIAO CG, Liang XH, Ke Y, Yao L, et al
    Active demethylation upregulates CD147 expression promoting non-small cell lung cancer invasion and metastasis.
    Oncogene. 2022 Feb 7. pii: 10.1038/s41388-022-02213.
    PubMed     Abstract available
    
    
    
62. JIN Y, Pan Y, Zheng S, Liu Y, et al
    Inactivation of EGLN3 hydroxylase facilitates Erk3 degradation via autophagy and impedes lung cancer growth.
    Oncogene. 2022 Feb 5. pii: 10.1038/s41388-022-02203.
    PubMed     Abstract available
    
    
    
63. CHO HC, Huang Y, Hung JT, Hung TH, et al
    Puf-A promotes cancer progression by interacting with nucleophosmin in nucleolus.
    Oncogene. 2022;41:1155-1165.
    PubMed     Abstract available
    
    
    January 2022
64. MEINHARDT AL, Munkhbaatar E, Hockendorf U, Dietzen M, et al
    The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner.
    Oncogene. 2022 Jan 29. pii: 10.1038/s41388-021-02161.
    PubMed     Abstract available
    
    
    
65. JIN X, Zhang B, Zhang H, Yu H, et al
    Smoking-associated upregulation of CBX3 suppresses ARHGAP24 expression to activate Rac1 signaling and promote tumor progression in lung adenocarcinoma.
    Oncogene. 2022;41:538-549.
    PubMed     Abstract available
    
    
    
66. ALAM SK, Zhang Y, Wang L, Zhu Z, et al
    DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma.
    Oncogene. 2022;41:83-98.
    PubMed     Abstract available
    
    
    December 2021
67. ALHAYYANI S, McLeod L, West AC, Balic JJ, et al
    Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer.
    Oncogene. 2021 Dec 3. pii: 10.1038/s41388-021-02134.
    PubMed     Abstract available
    
    
    
68. BISCHOFF P, Trinks A, Obermayer B, Pett JP, et al
    Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma.
    Oncogene. 2021;40:6748-6758.
    PubMed     Abstract available
    
    
    
69. LIU R, Gou D, Xiang J, Pan X, et al
    O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis.
    Oncogene. 2021;40:6707-6719.
    PubMed     Abstract available
    
    
    
70. CHEN Z, Yu D, Owonikoko TK, Ramalingam SS, et al
    Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.
    Oncogene. 2021;40:6653-6665.
    PubMed     Abstract available
    
    
    November 2021
71. SHIN DH, Kim SH, Choi M, Bae YK, et al
    Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1.
    Oncogene. 2021 Nov 6. pii: 10.1038/s41388-021-02097.
    PubMed     Abstract available
    
    
    
72. LI M, Li X, Goldsmith JR, Shi S, et al
    Decoupling tumor cell metastasis from growth by cellular pilot protein TNFAIP8.
    Oncogene. 2021;40:6456-6468.
    PubMed     Abstract available
    
    
    
73. ROUKENS MG, Frederiks CL, Seinstra D, Braccioli L, et al
    Regulation of a progenitor gene program by SOX4 is essential for mammary tumor proliferation.
    Oncogene. 2021;40:6343-6353.
    PubMed     Abstract available
    
    
    October 2021
74. INGRAM K, Samson SC, Zewdu R, Zitnay RG, et al
    NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity.
    Oncogene. 2021 Oct 23. pii: 10.1038/s41388-021-02076.
    PubMed     Abstract available
    
    
    
75. CHEN J, Guanizo A, Luong Q, Jayasekara WSN, et al
    Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium.
    Oncogene. 2021 Oct 21. pii: 10.1038/s41388-021-02070.
    PubMed     Abstract available
    
    
    
76. LIANG SK, Hsu CC, Song HL, Huang YC, et al
    Correction: FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis.
    Oncogene. 2021 Oct 12. pii: 10.1038/s41388-021-02044.
    PubMed    
    
    
    September 2021
77. TAKAGI S, Sasaki Y, Koike S, Takemoto A, et al
    Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis.
    Oncogene. 2021;40:5548-5558.
    PubMed     Abstract available
    
    
    
78. XU G, Yang Z, Ding Y, Liu Y, et al
    The deubiquitinase USP16 functions as an oncogenic factor in K-RAS-driven lung tumorigenesis.
    Oncogene. 2021;40:5482-5494.
    PubMed     Abstract available
    
    
    August 2021
79. LEONARD MK, Puts GS, Pamidimukkala N, Adhikary G, et al
    Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.
    Oncogene. 2021 Aug 25. pii: 10.1038/s41388-021-01998.
    PubMed     Abstract available
    
    
    
80. MELOCCHI V, Dama E, Mazzarelli F, Cuttano R, et al
    Aggressive early-stage lung adenocarcinoma is characterized by epithelial cell plasticity with acquirement of stem-like traits and immune evasion phenotype.
    Oncogene. 2021;40:4980-4991.
    PubMed     Abstract available
    
    
    July 2021
81. CHEN CH, Wang BW, Hsiao YC, Wu CY, et al
    PKCdelta-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs.
    Oncogene. 2021;40:4796-4808.
    PubMed     Abstract available
    
    
    
82. WU J, Li L, Zhang H, Zhao Y, et al
    A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.
    Oncogene. 2021;40:4413-4424.
    PubMed     Abstract available
    
    
    June 2021
83. LIANG SK, Hsu CC, Song HL, Huang YC, et al
    FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis.
    Oncogene. 2021 Jun 21. pii: 10.1038/s41388-021-01895.
    PubMed     Abstract available
    
    
    
84. LIU W, Huang Y, Wang D, Han F, et al
    MPDZ as a novel epigenetic silenced tumor suppressor inhibits growth and progression of lung cancer through the Hippo-YAP pathway.
    Oncogene. 2021 Jun 9. pii: 10.1038/s41388-021-01857.
    PubMed     Abstract available
    
    
    
85. YANG X, Chen Y, Zhou Y, Wu C, et al
    GPC5 suppresses lung cancer progression and metastasis via intracellular CTDSP1/AhR/ARNT signaling axis and extracellular exosome secretion.
    Oncogene. 2021 Jun 2. pii: 10.1038/s41388-021-01837.
    PubMed     Abstract available
    
    
    
86. LI M, Shi M, Hu C, Chen B, et al
    MALAT1 modulated FOXP3 ubiquitination then affected GINS1 transcription and drived NSCLC proliferation.
    Oncogene. 2021;40:3870-3884.
    PubMed     Abstract available
    
    
    May 2021
87. XU Q, Zhang J, Telfer BA, Zhang H, et al
    The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion.
    Oncogene. 2021 May 12. pii: 10.1038/s41388-021-01798.
    PubMed     Abstract available
    
    
    
88. VENUGOPALAN A, Lynberg M, Cultraro CM, Nguyen KDP, et al
    SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma.
    Oncogene. 2021;40:3331-3346.
    PubMed     Abstract available
    
    
    
89. RANGEL DF, Dubeau L, Park R, Chan P, et al
    Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis.
    Oncogene. 2021;40:3624-3632.
    PubMed     Abstract available
    
    
    
90. ZHANG Q, Tang Q, Liu W, Hu C, et al
    Novel role of CAP1 in regulation RNA polymerase II-mediated transcription elongation depends on its actin-depolymerization activity in nucleoplasm.
    Oncogene. 2021;40:3492-3509.
    PubMed     Abstract available
    
    
    
91. WU S, Liu B, Zhang Y, Hong R, et al
    Long non-coding RNA LEISA promotes progression of lung adenocarcinoma via enhancing interaction between STAT3 and IL-6 promoter.
    Oncogene. 2021;40:3449-3459.
    PubMed     Abstract available
    
    
    April 2021
92. XU L, Liu W, Li T, Hu Y, et al
    Long non-coding RNA SMASR inhibits the EMT by negatively regulating TGF-beta/Smad signaling pathway in lung cancer.
    Oncogene. 2021 Apr 30. pii: 10.1038/s41388-021-01760.
    PubMed     Abstract available
    
    
    
93. ALI MM, Di Marco M, Mahale S, Jachimowicz D, et al
    LY6K-AS lncRNA is a lung adenocarcinoma prognostic biomarker and regulator of mitotic progression.
    Oncogene. 2021;40:2463-2478.
    PubMed     Abstract available
    
    
    
94. PAN Y, Han H, Labbe KE, Zhang H, et al
    Recent advances in preclinical models for lung squamous cell carcinoma.
    Oncogene. 2021;40:2817-2829.
    PubMed     Abstract available
    
    
    
95. MA S, Zhang L, Ren Y, Dai W, et al
    Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer.
    Oncogene. 2021;40:2596-2609.
    PubMed     Abstract available
    
    
    March 2021
96. MENG C, Zhan J, Chen D, Shao G, et al
    The deubiquitinase USP11 regulates cell proliferation and ferroptotic cell death via stabilization of NRF2 USP11 deubiquitinates and stabilizes NRF2.
    Oncogene. 2021;40:1706-1720.
    PubMed     Abstract available
    
    
    
97. TURGU B, Zhang F, El-Naggar A, Negri GL, et al
    HACE1 blocks HIF1alpha accumulation under hypoxia in a RAC1 dependent manner.
    Oncogene. 2021;40:1988-2001.
    PubMed     Abstract available
    
    
    
98. CHEN L, Zhang Y, Shu X, Chen Q, et al
    Proteasome regulation by reversible tyrosine phosphorylation at the membrane.
    Oncogene. 2021;40:1942-1956.
    PubMed     Abstract available
    
    
    
99. GUO Z, Dai Y, Hu W, Zhang Y, et al
    The long noncoding RNA CRYBG3 induces aneuploidy by interfering with spindle assembly checkpoint via direct binding with Bub3.
    Oncogene. 2021;40:1821-1835.
    PubMed     Abstract available
    
    
    February 2021
100. WU R, Li K, Yuan M, Luo KQ, et al
     Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells.
     Oncogene. 2021 Feb 24. pii: 10.1038/s41388-021-01691.
     PubMed     Abstract available
     
     
     
101. LIU PI, Chang AC, Lai JL, Lin TH, et al
     Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases.
     Oncogene. 2021;40:1503-1515.
     PubMed     Abstract available
     
     
     
102. CHENG FJ, Chen CH, Tsai WC, Wang BW, et al
     Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC.
     Oncogene. 2021;40:1162-1175.
     PubMed     Abstract available
     
     
     January 2021
103. ALSAFADI S, Dayot S, Tarin M, Houy A, et al
     Genetic alterations of SUGP1 mimic mutant-SF3B1 splice pattern in lung adenocarcinoma and other cancers.
     Oncogene. 2021;40:85-96.
     PubMed     Abstract available
     
     
     
104. HE D, Wang D, Lu P, Yang N, et al
     Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations.
     Oncogene. 2021;40:355-368.
     PubMed     Abstract available
     
     
     
105. TANG L, Xiong W, Zhang L, Wang D, et al
     circSETD3 regulates MAPRE1 through miR-615-5p and miR-1538 sponges to promote migration and invasion in nasopharyngeal carcinoma.
     Oncogene. 2021;40:307-321.
     PubMed     Abstract available
     
     
     
106. LIU X, Wang F, Xu C, Chen X, et al
     Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma.
     Oncogene. 2021;40:821-832.
     PubMed     Abstract available
     
     
     
107. LIN WH, Chang YW, Hong MX, Hsu TC, et al
     STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT-MET switch and cancer metastasis.
     Oncogene. 2021;40:791-805.
     PubMed     Abstract available
     
     
     
108. GUHA P, Gardell J, Rabinowitz B, Lopes M, et al
     Monocytic and granulocytic myeloid-derived suppressor cell plasticity and differentiation are organ-specific.
     Oncogene. 2021;40:693-704.
     PubMed     Abstract available
     
     
     October 2020
109. NIMMAKAYALA RK, Leon F, Rachagani S, Rauth S, et al
     Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.
     Oncogene. 2020 Oct 27. pii: 10.1038/s41388-020-01518.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.